Get the Stockscreener App
5.46
3.37%
-0.19
Immatics N V stock is traded at $5.46, with a volume of 159.07K.
It is down -3.37% in the last 24 hours and down -22.45% over the past month.
Immatics NV is a biotechnology company that is engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies.
See More
Previous Close:
$5.65
Open:
$5.64
24h Volume:
159.07K
Relative Volume:
0.21
Market Cap:
$686.76M
Revenue:
$58.49M
Net Income/Loss:
$-105.04M
P/E Ratio:
-4.201
EPS:
-1.2997
Net Cash Flow:
$-13.78M
1W Performance:
-0.19%
1M Performance:
-22.45%
6M Performance:
-50.64%
1Y Performance:
-51.03%
1-Day Range:
$5.415
$5.64
1-Week Range:
$5.195
$5.82
52-Week Range:
$5.195
$13.77
Immatics N V Stock (IMTX) Company Profile
Compare IMTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMTX
Immatics N V
|
5.46 | 686.76M | 58.49M | -105.04M | -13.78M | -1.2997 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.81 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
715.68 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
652.48 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.07 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.61 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Immatics N V Stock (IMTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-07-24 | Initiated | Piper Sandler | Overweight |
| Nov-02-23 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-31-23 | Initiated | Mizuho | Buy |
| Mar-24-23 | Initiated | Bryan Garnier | Buy |
| Nov-20-20 | Initiated | BofA Securities | Buy |
| Sep-22-20 | Initiated | Goldman | Buy |
| Jul-27-20 | Initiated | SVB Leerink | Outperform |
| Jul-24-20 | Initiated | Jefferies | Buy |
View All
Immatics N V Stock (IMTX) Latest News
Financial Metrics Check: Immatics N.V (IMTX)’s Ratios for Trailing Twelve Months - The Dwinnex
Examining Immatics N.V (IMTX) more closely is necessary - US Post News
It is Poised to be a Bull Market for Immatics N.V (IMTX) - SETE News
Immatics (NASDAQ:IMTX) Reaches New 1-Year LowWhat's Next? - MarketBeat
Immatics N.V (IMTX) Becoming More Attractive for Investors - Knox Daily
Immatics (NASDAQ:IMTX) Short Interest Up 13.1% in January - MarketBeat
Immatics (NASDAQ:IMTX) Hits New 52-Week LowShould You Sell? - MarketBeat
Immatics N.V (IMTX) Volatility Hits 4.72% – Here Is What You Should Do - Stocks Register
Contrasting BioCryst Pharmaceuticals (NASDAQ:BCRX) & Immatics (NASDAQ:IMTX) - Defense World
Brokers Offer Predictions for Immatics FY2025 Earnings - ETF Daily News
Immatics (NASDAQ:IMTX) Reaches New 52-Week LowTime to Sell? - MarketBeat
Cantor Fitzgerald Predicts Immatics FY2025 Earnings - Defense World
Cantor Fitzgerald Forecasts Immatics FY2025 Earnings - MarketBeat
Is Immatics N.V. (IMTX) Among Billionaire Joseph Edelman’s Long-Term Stock Picks? - Insider Monkey
Immatics (NASDAQ:IMTX) Short Interest Up 13.1% in December - MarketBeat
Immatics (NASDAQ:IMTX) Shares Sold by JPMorgan Chase & Co. - Defense World
Immatics (NASDAQ:IMTX) Shares Down 3.9%What's Next? - MarketBeat
Down -16.85% in 4 Weeks, Here's Why Immatics (IMTX) Looks Ripe for a Turnaround - Yahoo Finance
Revenues Working Against Immatics N.V.'s (NASDAQ:IMTX) Share Price - Simply Wall St
Immatics N.V.: Considering More Engineered T Cells For Cancer (NASDAQ:IMTX) - Seeking Alpha
IMTX: 3 Small-Cap Healthcare Stocks With Big Upside Potential - StockNews.com
Analyzing Immatics (NASDAQ:IMTX) & Kyverna Therapeutics (NASDAQ:KYTX) - Defense World
Immatics (IMTX) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
How to Take Advantage of moves in (IMTX) - Stock Traders Daily
State Street Corp Grows Position in Immatics (NASDAQ:IMTX) - Defense World
Immatics (NASDAQ:IMTX) & Achilles Therapeutics (NASDAQ:ACHL) Financial Survey - Defense World
ZTS: 3 Healthcare Innovators with Analyst-Endorsed Upside - StockNews.com
(IMTX) Technical Data - Stock Traders Daily
Immatics (NASDAQ:IMTXW) Stock Price Down 0.7% – Time to Sell? - Defense World
Comparing Calidi Biotherapeutics (NYSE:CLDI) & Immatics (NASDAQ:IMTX) - Defense World
Immatics (NASDAQ:IMTX) Hits New 12-Month LowWhat's Next? - MarketBeat
Immatics (NASDAQ:IMTX) Sees Significant Increase in Short Interest - MarketBeat
(IMTX) Technical Pivots with Risk Controls - Stock Traders Daily
Immatics (NASDAQ:IMTX) Trading Down 4.2%What's Next? - MarketBeat
Immatics Faces Termination of Key Collaboration with Bristol Myers Squibb - TipRanks
Immatics (NASDAQ:IMTX) Shares Bought by Frazier Life Sciences Management L.P. - MarketBeat
Wellington Management Group LLP Has $110.46 Million Stock Holdings in Immatics (NASDAQ:IMTX) - MarketBeat
The Manufacturers Life Insurance Company Grows Stock Position in Immatics (NASDAQ:IMTX) - Defense World
Reviewing bluebird bio (NASDAQ:BLUE) and Immatics (NASDAQ:IMTX) - Defense World
Why Is Immatics N.V. (IMTX) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds? - Yahoo Finance
Walleye Capital LLC Lowers Stock Holdings in Immatics (NASDAQ:IMTX) - MarketBeat
Braidwell LP Makes New $18.80 Million Investment in Immatics (NASDAQ:IMTX) - MarketBeat
Immatics NV (FRA:4A3) EBITDA per Share : €-0.40 (TTM As of Sep. 2024) - GuruFocus.com
Vestal Point Capital LP Grows Stock Holdings in Immatics (NASDAQ:IMTX) - MarketBeat
Immatics (NASDAQ:IMTX) Upgraded by The Goldman Sachs Group to "Strong-Buy" Rating - MarketBeat
Exscientia (NASDAQ:EXAI) & Immatics (NASDAQ:IMTX) Head to Head Comparison - Defense World
Immatics N V Stock (IMTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):